Research Article
Pentraxin-3 Predicts Long-Term Cardiac Events in Patients with Chronic Heart Failure
Table 1
Clinical characteristics of patients with and without a cardiac event.
| | All patients () | Event-free () | Cardiac event () | value |
| Age (years) | | | | <0.001 | Males, (%) | 220 (58.5) | 131 (58.2) | 89 (58.6) | 0.5175 | Heart rate, beats/min | | | | <0.001 | NYHA class >II, (%) | 266 (70.7) | 134 (59.6) | 129 (84.9) | <0.001 | CHD, (%) | 196 (52.1) | 114 (50.7) | 82 (53.8) | 0.599 | Diabetes mellitus, (%) | 52 (13.8) | 29 (12.9) | 23 (15.1) | 0.546 | Hypertension, (%) | 143 (38.0) | 89 (39.6) | 54 (35.5) | 0.450 | Hyperlipidemia, (%) | 94 (25.0) | 54 (24.0) | 40 (26.3) | 0.629 | Current smoking, (%) | 115 (30.6) | 68 (30.2) | 47 (30.9) | 0.910 | PTX3 (ng/mL) | | | | <0.001 | cTnI (ng/mL) | | | | <0.001 | hsCRP (ng/mL) | | | | <0.001 | Medical therapy | | | | | Aspirin, (%) | 349 (92.8) | 204 (90.6) | 145 (95.4) | 0.211 | β-blockers, (%) | 254 (67.6) | 160 (71.1) | 94 (61.8) | 0.073 | ACE-I/ARB, (%) | 266 (70.7) | 169 (75.1) | 97 (63.8) | 0.021 | Diuretics, (%) | 344 (91.5) | 204 (90.7) | 140 (92.1) | 0.712 |
|
|